CIPLA, after its recent victory in the Delhi HC is all inspired to spread its wings out further. As per a recent report in The Hindu, CIPLA is all set to sell a generic version of Deferasirox. Deferasirox, originally a Novartis drug, is sold internationally under the Exjade brand name and is useful for treatment of iron overload that occurs due to blood transfusions. It is therefore particularly useful for patients suffering from thalassemia and other such conditions.
As per the report, Novartis plans to launch Exjade in India in the second quarter of 2008 and Cipla’s version will be sold locally under the brand name Desirox and will cost consumers about Rs. 1000 per month.
Novartis has applied for a patent on Deferasirox in India and all are expecting a fresh spate of patent litigation involving CIPLA. Lawyers and academicians atleast are looking forward to this!